Search

Methapyrilene

Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

Glyceryl monostearate

Glycerol monostearate, commonly known as GMS, is the glycerol ester of stearic acid . It is commonly used as an emulsifier in foods.

Promestriene

Promestriene has been studied in phase IV of the clinical trial on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security in patients with vaginitis … In addition, promestriene was in phase IV of the clinical trial to study its treatment of patients with vaginosis, bacterial, but that studied was terminated.

Ferrous sulfate anhydrous

[A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells.

Glasdegib

Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).

Siplizumab

Deanol

It has been also used as an ingredient in skin care, and in cognitive function- and mood-enhancing products. … Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups.

Benzododecinium

Benzododecinium is used as an antiseptic/disinfectant compound. It has been marketed as a tincture for antiseptic product for wounds in the Czech Republic.

Dinutuximab

Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Enfortumab vedotin

The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December … [L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000]